Sudarshan Pharma Industries Ltd strategy deck summary

Strategy deck of 14 Aug 2026, summarised by AI from the filing.

Sudarshan Pharma filed an updated presentation on the proposed acquisition of a USFDA-approved API and intermediates plant with 584 KL total capacity.

Key takeaways

1. Acquisition The company filed an updated presentation on the manufacturing plant proposed to be acquired, a USFDA-approved API and intermediates unit in Andhra Pradesh.
2. Approvals The site was audited and accepted by WHO Geneva in 2024, approved by USFDA (ANDA-217608) in 2024 and approved by ANVISA in 2025.
3. Capacity The facility has 4 manufacturing blocks and a solvent recovery plant, with total capacity of 584 KL.
4. Products The site manufactures API and API intermediates, including intermediates for antiretroviral, antifungal and other therapies.
5. Customers Customers include export buyers such as Bayer Limited and domestic buyers such as Laurus Labs Limited, Cipla Limited and Dr. Reddy’s.

Original filing on BSE

Sudarshan Pharma Industries Ltd earnings call, investor presentation and press release summaries

• Q4 FY25: Results deck (2 May 2025)
• Other events: Strategy deck (18 Aug 2026), Strategy deck (14 Aug 2026), Strategy deck (15 May 2026), Strategy deck (31 Jan 2026), Strategy deck (14 Aug 2025)